Business news

Cell-Free DNA Testing Market is Anticipated to Expand and Reach US$ 22.41 Billion by the end of 2027, At a CAGR of 26.2%

Cell-Free DNA Testing Market

According to a recent analysis by Emergen Research, the global Cell-Free DNA (cfDNA) Testing Market is expected to reach USD 22.41 billion by 2027. DNA fragments known as cell-free DNA are present in blood plasma and serve as useful biomarkers. A small amount of the patient’s saliva, urine, or blood is collected as part of a novel technology to evaluate the freely flowing DNA. Cell-Free DNA (cfDNA) is a non-invasive screening test used to identify mutations in cancer patients, detect graft rejection, and find different chromosomal abnormalities in foetuses to determine the gender of the foetus. The study of infectious illnesses, transplantation, obstetrics, and oncology have all seen new possibilities arise as a result of the discovery of cfDNA.

The increased rates of diseases including chromosomal anomalies due to an increase in maternal age, changing lifestyles, bad eating patterns, and an increase in the prevalence of cancer are pushing the market for cell-free DNA (cfDNA) testing. However, there are a number of factors impeding the market’s expansion, including a lack of standardisation, poor reimbursement practises, and legal and regulatory requirements. The market for cell-free DNA is also being driven by rising healthcare awareness and rising healthcare spending.

Key advancements in the cell-free DNA (cfDNA) testing market are discussed in the report, along with both organic and inorganic growth tactics. Many businesses are putting an emphasis on organic growth initiatives, including new launches, product approvals, and others like patents and events. Acquisitions and partnerships & collaborations were two examples of inorganic growth tactics in the market. These actions have made it possible for market participants to grow their consumer bases and operations. With the increasing demand for cell-free DNA (cfDNA) testing in the global market, it is projected that market players in the cell-free DNA (cfDNA) testing market would have profitable growth prospects in the future. The list of a few businesses active in the cell-free DNA (cfDNA) testing market is provided below.

Get a sample Copy

Some Key Highlights from the Report :

According to estimates, the circulating cell-free DNA (ccfDNA) diagnostics market will have the greatest revenue share in the non-invasive prenatal testing sector by 2022. The dominance of this market has been aided by the popularity of non-invasive tests based on cfDNA. Furthermore, the segment is being driven by increased medical coverage for NIPTs.

During the forecast period of 2022–2027, the hospitals & prenatal clinics segment is anticipated to hold the highest share in the global circulating cell-free DNA (ccfDNA) diagnostics market. The public’s understanding and acceptance of non-invasive prenatal DNA screening is growing, which has boosted this sector’s income flow. The hospitals & prenatal clinics remain the leading end-users of the market due to the benefits of NIPTs, such as early risk diagnosis of chromosomal defects like down syndrome and trisomy utilising NIPTs.

Because it can create a quantifiable profile of gene expression in cells or tissues, the MPSS technology category is predicted to dominate the global market with a CAGR of 26.7%.

The gynaecology sector is estimated to dominate the market during the projected period because the cell-free DNA method is being used to diagnose pregnancy complications like miscarriage and to detect genetic problems with the unborn child.

Key participants include Sequenom, Inc., Quest Diagnostics, Illumina Inc., Agilent Technologies, Inc., Guardant Health, Inc., Biodesix, Inc., Allenex AB, Roche Holdings AG, Biocept, Inc., and CareDx, Inc., among others.

Emergen Research has segmented the global Cell-Free DNA (cfDNA) Testing Market on the basis of type, technology, application, and region:

Type Outlook (Revenue, USD Billion; 2017-2027)

  • Cell-free fetal DNA (NIPT)
  • Circulating tumor DNA
  • Donor-derived cell-free DNA

Technology Outlook (Revenue, USD Billion; 2017-2027)

  • MPSS
  • t-MPS
  • SNP
  • Others

Application Outlook (Revenue, USD Billion; 2017-2027)

  • Transplantation
  • Gynecology
  • Oncology

Regional Outlook (Revenue, USD Billion; 2017-2027)

  • North America
    1. U.S.
    2. Canada
    3. Mexico
  • Europe
    1. Germany
    2. UK
    3. France
    4. BENELUX
    5. Rest of Europe
  • Asia Pacific
    1. China
    2. Japan
    3. South Korea
    4. Rest of APAC
  • Latin America
    1. Brazil
    2. Rest of LATAM
  • MEA
    1. Saudi Arabia
    2. UAE
    3. Rest of MEA

To get leading market solutions, Visit the Link

To Top

Pin It on Pinterest

Share This